Citation
Stoneham, Simon M., et al. "Thrombotic Risk in COVID-19: a Case Series and Case-control Study." Clinical Medicine (London, England), vol. 20, no. 4, 2020, pp. e76-e81.
Stoneham SM, Milne KM, Nuttall E, et al. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med (Lond). 2020;20(4):e76-e81.
Stoneham, S. M., Milne, K. M., Nuttall, E., Frew, G. H., Sturrock, B. R., Sivaloganathan, H., Ladikou, E. E., Drage, S., Phillips, B., Chevassut, T. J., & Eziefula, A. C. (2020). Thrombotic risk in COVID-19: a case series and case-control study. Clinical Medicine (London, England), 20(4), e76-e81. https://doi.org/10.7861/clinmed.2020-0228
Stoneham SM, et al. Thrombotic Risk in COVID-19: a Case Series and Case-control Study. Clin Med (Lond). 2020;20(4):e76-e81. PubMed PMID: 32423903.
TY - JOUR
T1 - Thrombotic risk in COVID-19: a case series and case-control study.
AU - Stoneham,Simon M,
AU - Milne,Kate M,
AU - Nuttall,Elisabeth,
AU - Frew,Georgina H,
AU - Sturrock,Beattie Rh,
AU - Sivaloganathan,Helena,
AU - Ladikou,Eleni E,
AU - Drage,Stephen,
AU - Phillips,Barbara,
AU - Chevassut,Timothy Jt,
AU - Eziefula,Alice C,
Y1 - 2020/05/18/
PY - 2020/5/20/pubmed
PY - 2020/8/4/medline
PY - 2020/5/20/entrez
KW - COVID-19
KW - D-dimer
KW - deep vein thrombosis
KW - pulmonary embolism
KW - venous thromboembolism
SP - e76
EP - e81
JF - Clinical medicine (London, England)
JO - Clin Med (Lond)
VL - 20
IS - 4
N2 - BACKGROUND: A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous thromboembolism (VTE) are extremely limited. METHODS: We describe three cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an inpatient cohort, and a case-control study to identify risk factors associated with VTE. RESULTS: We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were seen in confirmed VTE cases (4.1 vs 1.2 μg/mL, p<0.001). CONCLUSION: Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be beneficial in guiding management.
SN - 1473-4893
UR - https://www.unboundmedicine.com/medline/citation/32423903/Thrombotic_risk_in_COVID_19:_a_case_series_and_case_control_study_
DB - PRIME
DP - Unbound Medicine
ER -